

## PERSONAL INFORMATION

## Elia Sechi, MD, MS



📍 University of Sassari;  
Department of Medical, Surgical and Experimental Sciences  
Unit of Neurology  
Viale San Pietro, 10; 07100 Sassari (Italy)

H-Index on Scopus: 18

Last update: Mar 07, 2023

## EDUCATION AND TRAINING

January 2021-Present

**Neurology Consultant**

Neurology Unit; Department of Medical, Surgical and Experimental Sciences  
University of Sassari, Sassari (Italy)

June 2017-January 2021

**Clinical Research Fellowship in Autoimmune Neurology and Multiple Sclerosis**

Mayo Clinic, Rochester, MN (USA)  
Mentor: E.P. Flanagan

June 2017-October 2019

**Master in Biomedical Sciences - Clinical and Translational Science**

Mayo Clinic, Rochester, MN (USA)  
Mentor: S.J. Pittock

August 2013-August 2018

**Residency in Neurology**

University of Sassari, Sassari (Italy)  
Finale grade: 50/50 cum laude

September 2006-October 2012

**Medical School**

University of Sassari, Sassari (Italy)  
Final grade: 110/110 cum laude

Jun 1, 2022

**Italia National Scientific Habilitation (ASN) – Associate Professor of Neurology**

(Abilitazione Scientifica Nazionale a Professore di II Fascia)  
Settore 06/D6 – Neurologia  
Bando D.D. 553/2021

March 2020-January 2021

**Assistant Professor of Neurology**

Mayo Clinic College of Medicine  
Mayo Clinic, Rochester, MN (USA)

## ACADEMIC TITLES AND POSITIONS

## PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2

[Related document\(s\):](#)

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2: Proficient user  
[Common European Framework of Reference for Languages](#)

Computer/instrumental skills Advanced command of Microsoft® Windows and Office package (Word, Excel, PowerPoint).  
Advanced command of JMP® Pro.  
Head and neck Doppler ultrasonography (basic).

Expertise Inflammatory/autoimmune CNS disorders, Multiple Sclerosis, Myelopathies

## PUBLICATIONS

Peer-reviewed publications in international journals

1. **Sechi E**, Defazio G, Erre GL, Solla P. *Author Response: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis*. *Neurology*. 2023 Feb 7;100(6):311-312. doi: 10.1212/WNL.0000000000206851.
2. Cacciaguerra L, Morris P, Tobin WO, Chen JJ, Banks SA, Elsbernd P, Redenbaugh V, Tillemma JM, Montini F, **Sechi E**, Lopez-Chiriboga AS, Zalewski N, Guo Y, Rocca MA, Filippi M, Pittock SJ, Lucchinetti CF, Flanagan EP. *Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder*. *Neurology*. 2023 Jan 23;10.1212/WNL.0000000000206820. doi: 10.1212/WNL.0000000000206820.
3. Carta S, Cobo Calvo Á, Armangué T, [...] **Sechi E**, Flanagan EP, Pittock SJ, Redenbaugh V, Reindl M, Marignier R, Mariotto S. *Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study*. *Neurology*. 2022 Dec 16;10.1212/WNL.0000000000201662. doi: 10.1212/WNL.0000000000201662.
4. Fadda G, Flanagan EP, **Sechi E**. *Editorial: Immune-mediated disorders of the spinal cord: Diagnosis, treatment strategies, and outcomes in the 21st century*. *Front Neurol*. 2022 Nov 29;13:1087631. doi: 10.3389/fneur.2022.1087631.
5. Filippi M, Preziosa P, Arnold DL, Barkhof F, Harrison DM, Maggi P, Mainero C, Montalban X, **Sechi E**, Weinshenker BG, Rocca MA. *Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective*. *J Neurol*. 2023 Mar;270(3):1286-1299.
6. Fadda G, Flanagan EP, Cacciaguerra L, Jitrapaikulsan J, Solla P, Zara P, **Sechi E**. *Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD*. *Front Neurol* 2022. doi: 10.3389/fneur.2022.1011579.

7. Valencia-Sanchez C, Guo Y, Krecke KN, Chen JJ, Redenbaugh V, Montalvo M, Elsbernd PM, Tillema JM, Lopez-Chiriboga S, Budhram A, **Sechi E**, et al. *Cerebral cortical encephalitis in MOGAD*. *Ann Neurol* 2022. doi: 10.1002/ana.26549.
8. Cacciaguerra L, **Sechi E**, Rocca MA, Filippi M, Pittock SJ, Flanagan EP. *Neuroimaging features in inflammatory myelopathies: A review*. *Front Neurol* 2022. doi: 10.3389/fneur.2022.993645.
9. Spagni G, Sun B, Monte G, **Sechi E**, Iorio R, Evoli A, Damato V. *Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis*. *J Neurol Neurosurg Psychiatry* 2022. doi: 10.1136/jnnp-2022-330086.
10. Syc-Mazurek S, Chen JJ, Morris P, **Sechi E**, et al. *Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease*. *Neurology* 2022. doi: 10.1212/WNL.0000000000201263.
11. **Sechi E**, Cacciaguerra L, Chen JJ, et al. *Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI features, Diagnosis, and Management*. *Front Neurol* 2022. doi: 10.3389/fneur.2022.885218.
12. **Sechi E**, Gallus E, Solla P, et al. *Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis*. *Neurology* 2022. doi: 10.1212/WNL.0000000000200837.
13. Dinoto A, Gastaldi M, Iorio R, Marini S, Damato V, Farina A, Zoccarato M, **Sechi E**, et al. *Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders*. *Mult Scler Relat Disord*. 2022 Apr 25;63:103827. doi: 10.1016/j.msard.2022.103827.
14. Dinoto A, **Sechi E**, Flanagan EP, Ferrari S, Solla P, Mariotto S, Chen JJ. *Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease*. *Front Neurol*. 2022 Mar 23;13:866824. doi: 10.3389/fneur.2022.866824.
15. Dinoto A, **Sechi E**, Ferrari S, et al. *Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD*. *Mult Scler Relat Disord* 2022. doi: 10.1016/j.msard.2021.103424.
16. Solla P, Ercoli T, Masala C, Orofino G, Fadda L, Corda DG, Zarbo IR, Meloni M, **Sechi E**, Bagella CF, Defazio G. *Rasagiline Withdrawal Syndrome in Parkinson's Disease*. *Brain Sci*. 2022; 12(2):219. doi: 10.3390/brainsci12020219.
17. Barakat B, Messina S, Nayak S, Kassa R, **Sechi E**, et al. *Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions*. *Mult Scler J Exp Transl Clin*. 2022 Jan 12;8(1):20552173211052159. doi: 10.1177/20552173211052159.
18. Bagella CF, Corda DG, Zara P, Elia AE, Ruiu E, **Sechi E**, Solla P. *Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination*. *Vaccines (Basel)*. 2021 Dec 19;9(12):1502.
19. Redenbaugh V, Montalvo M, **Sechi E**, et al. *Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders*. *Mult Scler J Exp Transl Clin*. 2021 Nov 26;7(4):20552173211052656. doi: 10.1177/20552173211052656.
20. Dominguez L, Collazo IVM, **Sechi E**, Bohm P, Chiriboga SL. *Neurochondrin immunoglobulin G - Associated myelopathy - Ataxia syndrome*. *J Neurol Sci*. 2022; 432:120058. doi:

10.1016/j.jns.2021.120058.

21. Rodriguez A, Klein CJ, **Sechi E**, et al. *LG1 antibody encephalitis: acute treatment comparisons and outcome*. J Neurol Neurosurg Psychiatry. 2022;93(3):309-315.
22. Zara P, Floris V, Flanagan EP, Lopez-Chiriboga AS, Weinschenker BG, Solla P, **Sechi E**. *Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI*. Mult Scler J Exp Transl Clin. 2021 Nov 19;7(4):20552173211048761. doi: 10.1177/20552173211048761.
23. Redenbaugh V, Flanagan EP, Floris V, [...] and **Sechi E**. *Exposure to TNF inhibitors is rare at MOGAD presentation*. J Neurol Sci. 2022 Jan 15;432:120044. doi: 10.1016/j.jns.2021.120044. Epub 2021 Oct 27.
24. **Sechi E**, Flanagan EP. *Evaluation and Management of Acute Myelopathy*. Semin Neurol. 2021 Oct;41(5):511-529.
25. Arru G, Galleri G, Deiana GA, Zarbo IR, **Sechi E**, et al. *HERV-K Modulates the Immune Response in ALS Patients*. Microorganisms. 2021 Aug 23;9(8):1784.
26. Zhao-Fleming HH, Valencia Sanchez C, **Sechi E**, et al. *CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies*. Neurology. 2021 Sep 28;97(13):e1351-e1358.
27. **Sechi E**, Flanagan EP. *Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management*. Front Neurol. 2021 Jul 7;12:673339. doi: 10.3389/fneur.2021.673339. eCollection 2021.
28. **Sechi E**, Zarbo R, Biancu MA, et al. *Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder*. J Neuroimmunol. 2021 Sep 15;358:577666. doi: 10.1016/j.jneuroim.2021.577666. Epub 2021 Jul 18.
29. **Sechi E**, Krecke KN, Messina SA, et al. *Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders*. Neurology. 2021 Sep 14;97(11):e1097-e1109.
30. **Sechi E**, Buciu M, Pittock SJ, et al. *Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing*. JAMA Neurol. 2021 Jun 1;78(6):741-746.
31. Banks SA, **Sechi E**, Flanagan EP. *Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression*. Ther Adv Neurol Disord. 2021 Mar 19;14:1756286421998906. doi: 10.1177/1756286421998906. eCollection 2021.
32. Budhram A, **Sechi E**, Flanagan EP, et al. *Clinical spectrum of high-titre GAD65 antibodies*. J Neurol Neurosurg Psychiatry. 2021 Feb 9;jnnp-2020-325275. doi: 10.1136/jnnp-2020-325275. Online ahead of print.
33. Mustafa R, Passe TJ, Lopez-Chiriboga AS, Weinschenker BG, Krecke KN, Zalewski NL, Diehn FE, **Sechi E**, [...] Flanagan EP. *Utility of MRI Enhancement Pattern in Myelopathies with Longitudinally-extensive T2-lesions*. Neurol Clin Pract 2021; First published January 25, 2021, DOI: <https://doi.org/10.1212/CPJ.0000000000001036>.
34. **Sechi E**, Mariotto S, McKeon A, et al. *Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis*. Stroke. 2021 Jan;52(2):645-654. doi: 10.1161/STROKEAHA.120.031482. Epub 2021 Jan 11.

35. Banks SA, Morris PP, Chen JJ, Pittock SJ, **Sechi E**, et al. *Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS*. J Neurol Neurosurg Psychiatry. 2020 Dec 28;jnnp-2020-325121. doi: 10.1136/jnnp-2020-325121. Online ahead of print.
36. **Sechi E**, Buciu M, Flanagan EP, et al. *Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder*. Mult Scler Relat Disord. 2021 Jan;47:102638. doi: 10.1016/j.msard.2020.102638. Epub 2020 Nov 23.
37. Budhram A, Dubey D, **Sechi E**, et al. *Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis*. Clin Chem. 2020 Nov 22;hvaa254. doi: 10.1093/clinchem/hvaa254. Online ahead of print.
38. **Sechi E**, Zekeridou A. *Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies*. J Thorac Oncol. 2021 Mar;16(3):381-394. doi: 10.1016/j.jtho.2020.11.005. Epub 2020 Nov 11.
39. Berti A, Moura MC, **Sechi E**, et al. *Beyond Giant Cell Arteritis and Takayasu's Arteritis: Secondary Large Vessel Vasculitis and Vasculitis Mimickers*. *Beyond Giant Cell Arteritis and Takayasu's Arteritis: Secondary Large Vessel Vasculitis and Vasculitis Mimickers*. Curr Rheumatol Rep. 2020 Nov 7;22(12):88. doi: 10.1007/s11926-020-00965-w.
40. Sun MM, Seleme N, Chen JJ, Zekeridou A, **Sechi E**, [...] Gordon LK. *Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade*. J Neuroophthalmol. 2020 Oct 28. doi: 10.1097/WNO.0000000000001148. Online ahead of print.
41. Buciu M, **Sechi E**, Flanagan EP, Lopez-Chiriboga AS. *Unfavorable outcome in highly relapsing MOGAD encephalitis*. J Neurol Sci. 2020 Nov 15;418:117088. doi: 10.1016/j.jns.2020.117088. Epub 2020 Aug 10.
42. Lopez-Chiriboga AS, **Sechi E**, Buciu M, et al. *Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder*. JAMA Neurol. 2020 Aug 31;77(12):1575-1577. doi: 10.1001/jamaneurol.2020.3115. Online ahead of print.
43. Nayak S, **Sechi E**, Flanagan EP, et al. *Inflammatory activity following motor progression due to critical CNS demyelinating lesions*. Mult Scler. 2020 Aug 19;1352458520948745. doi: 10.1177/1352458520948745. Online ahead of print.
44. **Sechi E**, Markovic SN, McKeon A, et al. *Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes*. Neurology. 2020 Oct 27;95(17):e2442-e2452. doi: 10.1212/WNL.0000000000010632. Epub 2020 Aug 13.
45. Kassa RM, **Sechi E**, Flanagan EP, et al. *Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions*. Mult Scler. 2020 Jul 15;1352458520940983. doi: 10.1177/1352458520940983. Online ahead of print.
46. Mariotto S, **Sechi E**, Ferrari S. *Serum neurofilament light chain studies in neurological disorders, hints for interpretation*. J Neurol Sci. 2020 Sep 15;416:116986. doi: 10.1016/j.jns.2020.116986. Epub 2020 Jun 14.
47. Budhram A, **Sechi E**, Nguyen A, et al. *FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis With Seizures (FLAMES): Is immunotherapy always needed to put out the fire?* Mult Scler Relat Disord. 2020 Sep;44:102283. doi: 10.1016/j.msard.2020.102283. Epub 2020 Jun 11

48. **Sechi E**, Messina S, Keegan BM, et al. *Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study*. *Mult Scler* 2021 Apr;27(5):667-673. doi: 10.1177/1352458520929192. Epub 2020 Jun 18.
49. Orlandi R, Mariotto S, Ferrari S, Gobbin F, **Sechi E**, [...] Gajofatto A. *Diagnostic features of initial demyelinating events associated with serum MOG-IgG*. *J Neuroimmunol* 2020 Jul 15;344:577260. doi: 10.1016/j.jneuroim.2020.577260. Epub 2020 May 7.
50. **Sechi E**, Flanagan EP. *Spinal arteriovenous fistula's often misdiagnosed as myelitis; can we stem the flow?* *J Neurol Sci*. 2020 Jun 15;413:116868. doi: 10.1016/j.jns.2020.116868. Epub 2020 Apr 30.
51. **Sechi E**, Krecke, KN, Pittock SJ, et al. *Frequency and Characteristics of MRI-Negative Myelitis Associated with MOG Autoantibody*. *Mult Scler* 2021 Feb;27(2):303-308.
52. Arru G, **Sechi E**, Mariotto S, et al. *Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD*. *J Neuroimmunol*. 2020 Jan 15;338:577110. doi: 10.1016/j.jneuroim.2019.577110.
53. Asnafi S, Morris PP, **Sechi E**, et al. *The frequency of longitudinally extensive transverse myelitis in MS: A population-based study*. *Mult Scler Relat Disord*. 2019 Oct 31;37:101487. doi: 10.1016/j.msard.2019.101487.
54. Lepedda AJ, Deiana GA, Lobina O, Nieddu G, Baldinu P, De Muro P, Andreetta F, **Sechi E**, Arru G, Corda DG, Sechi GP, Formato M. *Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and pathophysiological potential*. *J Circ Biomark*. 2019 Sep 11;8:1849454419875912. doi: 10.1177/1849454419875912.
55. **Sechi E**, Keegan BM, Kaufmann TJ, Kantarci OH, Weinschenker BG, Flanagan EP. *Unilateral Motor Progression in MS: Association with a Critical Corticospinal Tract Lesion*. *Neurology* 2019, in press.
56. Mariotto S, Gajofatto A, Zuliani L, [...] **Sechi E**, Monaco S, Ferrari S. *Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis*. *J Neurol* 2019. <https://doi.org/10.1007/s00415-019-09306-z>.
57. **Sechi E**, Shosha E, Williams JP, Pittock SJ, Weinschenker BG, Keegan BM, Zalewski NL, Lopez-Chiriboga AS, Jitprapaikulsan J, Flanagan EP. *Aquaporin-4 and MOG Autoantibody Discovery in Idiopathic Transverse Myelitis Epidemiology*. *Neurology* 2019, in press.
58. Mariotto S, Ferrari S, Gastaldi M, Franciotta D, **Sechi E**, et al. *Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders*. *J Neurol Neurosurg Psychiatry* 2019, in press.
59. **Sechi E**, Flanagan EP. *Diagnosis and Management of Autoimmune Dementia*. *Curr Treat Options Neurol* 2019;21(3):11.
60. **Sechi E**, Parks NE, Koeller KK, Flanagan EP. *Hypertrophic Olivary Degeneration Mimics Relapse in Neuromyelitis Optica Spectrum Disorder*. *Neurology* 2019;92(7):343-344.
61. **Sechi E**, Flanagan EP. *Area postrema syndrome in autoimmune GFAP astrocytopathy*. *Mult Scler* 2019. doi: 10.1177/1352458519826489. [Epub ahead of print].
62. Dubey D, Pittock SJ, Krecke KN, Morris PP, **Sechi E**, [...] Flanagan EP. *Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody*. *JAMA Neurol*. Published online December 21, 2018. doi:10.1001/jamaneurol.2018.4053.



63. **Sechi E**, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinschenker BG, Aksamit AJ, [...] Zekeridou A, Wingerchuk DM, Jitprapaikulsan J, Flanagan EP. *Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis*. J Neurol Neurosurg Psychiatry 2018 Jul 21. pii: jnnp-2018-318004. doi: 10.1136/jnnp-2018-318004.
64. **Sechi E**, Keegan BM, Flanagan EP. *Applying the 2017 McDonald diagnostic criteria for multiple sclerosis*. Lancet Neurol. 2018 Jun;17(6):498-499.
65. Arru G, Mameli G, Deiana GA, Rassu AL, Piredda R, **Sechi E**, [...] Sechi LA. *Humoral immunity response to human endogenous retroviruses K/W differentiates between amyotrophic lateral sclerosis and other neurological diseases*. Eur J Neurol. 2018 Mar 31. doi: 10.1111/ene.13648. [Epub ahead of print]
66. Bo M, Niegowska M, Arru G, **Sechi E**, [...] Sechi LA. *Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder*. J Neuroimmunol. 2018 May 15;318:97-102.
67. Arru G, **Sechi E**, Mariotto S, [...] Mameli G, Sechi LA, Sechi G. *Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder*. Mult Scler J Exp Transl Clin (Accepted for publication Oct 2017).
68. Mariotto S, Ferrari S, Monaco S, [...] **Sechi E**, Urso D, Delogu R, Janes F, Deotto L, Cadaldini M, Bianchi MR, Cantalupo G, Reindl M, Gajofatto A. *Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study*. J Neurol (Accepted for publication Oct 2017).
69. **Sechi E**, Addis A, Batzu L, Mariotto S, Ferrari S, Conti M, Sechi G. *Late presentation of NMOSD as rapidly progressive leukoencephalopathy with atypical clinical and radiological findings*. Mult Scler First published date: August-17-2017; doi: 10.1177/1352458517721661.
70. Doneddu PE, **Sechi E**, Addis A, Fadda G, Fois C, Sechi G. *Cranial Nerve Involvement in Neuralgic Amyotrophy*. J Neurol Neurophysiol 2016; 7:399.
71. Fois C, Rassu AL, Mandia D, **Sechi E**, Doneddu PE, Sechi G. *Paradoxical Effect of Levetiracetam in Newly Diagnosed Type II Focal Cortical Dysplasia*. Clin Neuropharmacol 2016; 39(5):265-268.
72. Sechi G, **Sechi E**, Fois C, Kumar N. *Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults*. Nutr Rev 2016; 74(5):281-300.
73. **Sechi E**, Addis A, Piredda R, Rassu AL, Mameli G, Senes C, Sechi G. *Longitudinally Extensive Spinal Cord Lesions Disclosing Occult Systemic Sarcoidosis*. JAMA Neurol 2016; 73(5):600-601.
74. Doneddu PE, **Sechi E**, Addis A, Fadda G, Fois C, Sechi G. *Neuralgic amyotrophy mimicking Vernet syndrome*. J Neurol Sci 2016; 362:230-231.
75. Fancellu L, Borsini W, Romani I, Pirisi A, Deiana GA, **Sechi E**, Doneddu PE, Rassu AL, Demurtas R, Scarabotto A, Cassini P, Arbustini E, Sechi G. *Exploratory screening for Fabry's disease in young adults with cerebrovascular disorders in northern Sardinia*. BMC Neurol 2015; 15:256.
76. **Sechi E**, Addis A, Fadda G, Minafra L, Bravatà V, Sechi G. *Teaching NeuroImages: Subacute encephalopathy in a young woman with THTR2 gene mutation*. Neurology 2015; 85(14):e108-109.

77. Sechi G, Fois C, Addis A, **Sechi E**. *Clinicopathologic features of folate-deficiency neuropathy*. *Neurology* 2015; 85(12):1090-1091.
78. Sechi G, **Sechi E**. *Restless legs syndrome and cerebrovascular disease*. *Lancet Neurol* 2013; 12(8):734.
79. Sechi G, Ceccherini I, Bachetti T, Deiana GA, **Sechi E**, Balbi P. *Ceftriaxone for Alexander's Disease: A Four-Year Follow-Up*. *JIMD Rep* 2013; 9:67-71.
80. Carai A, Fenu G, **Sechi E**, Crotti FM, Montella A. *Anatomical variability of the lateral femoral cutaneous nerve: findings from a surgical series*. *Clin Anat* 2009; 22(3):365-370.

Abstracts and Oral presentations  
at Professional Meetings,  
Conferences  
(International)

1. **Sechi E**. *Discussion of challenging cases*. Autoantibodies in Central and Peripheral Nervous System Disorders. (Verona March 25<sup>th</sup> 2022). Invited talk.
2. **Sechi E**. *Neurological complications of immunotherapies in oncology: Checkpoint inhibitors*. Neuroimmunology group 2021 - IMMUNOMEDIATE DISEASES OF THE NERVOUS SYSTEM: RECENT ADVANCES (Florence December 3<sup>th</sup>-4<sup>th</sup>). Invited talk.
3. **Sechi E**. *MOGAD*. MAGNETIC RESONANCE TECHNIQUES IN MULTIPLE SCLEROSIS - Twenty-third Advanced Course (Milan 3-4 November 2021). Invited talk.
4. **Sechi E**, Buciu M, Pittok SJ, et al. *The Positive Predictive Value of MOG Autoantibody Live Cell-Based Assay in a Tertiary Referral Center (4224)*. 73<sup>rd</sup> Meeting of the American Academy of Neurology; San Francisco 2021 (Virtual). Platform presentation.
5. Montalvo M, Pittock SJ, **Sechi E**, et al. *The Positive Predictive Value of Aquaporin-4 Antibody Live Cell-based Assay in a Tertiary Referral Center (1648)*. 73<sup>rd</sup> Meeting of the American Academy of Neurology; San Francisco 2021 (Virtual). Platform presentation.
6. **Sechi E**, Krecke K, Buciu M, et al. *Lesion Evolution on MRI in Myelitis Associated with MS, Aquaporin-4-IgG and Myelin Oligodendrocyte Glycoprotein-IgG (4913)*. 72<sup>nd</sup> Meeting of the American Academy of Neurology; Toronto 2020 (Virtual). Platform presentation.
7. **Sechi E**, Markovic SN, McKeon A, et al. *Neurological Complications and Neural Autoantibody Profiles Associated with Immune Checkpoint Inhibitors (4215)*. 72<sup>nd</sup> Meeting of the American Academy of Neurology; Toronto 2020 (Virtual). Platform presentation.
8. Zivelonghi C, McKeon A, **Sechi E**, et al. *AMPA Autoimmunity: Neurological, Oncological and Serological Accompaniments. (4689)*. 72<sup>nd</sup> Meeting of the American Academy of Neurology; Toronto 2020 (Virtual).
9. Kassa RM, **Sechi E**, Flanagan EP, et al. *Onset of Progressive Motor Impairment in Patients with Critical CNS Demyelinating Lesions (4405)*. 72<sup>nd</sup> Meeting of the American Academy of Neurology; Toronto 2020 (Virtual).
10. Zalewski NL, **Sechi E**, McKeon A, et al. *Serum Neurofilament Light Chain Levels Differentiate Spinal Cord Infarction from Inflammatory Myelitis (2620)*. 72<sup>nd</sup> Meeting of the American Academy of Neurology; Toronto 2020 (Virtual).
11. Lopez-Chiriboga AS, **Sechi E**, Buciu M, et al. *Long term outcomes in Myelin Oligodendrocyte Glycoprotein-IgG (MOG-IgG) Associated Disorders (1906)*. 72<sup>nd</sup> Meeting of the American Academy of Neurology; Toronto 2020 (Virtual). Platform presentation.



12. **Sechi E**, Messina S, Keegan BM, et al. A population-based comparison of cervical spine corticospinal tract lesions in benign and secondary progressive MS. ECTRIMS 2019 Stockholm. Poster (P1114).
13. **Sechi E**, Shosha E, Williams JP, Pittock SJ, Weinshenker BG, Keegan BM, Zalewski NL, Lopez-Chiriboga AS, Jitprapaikulsan J, Flanagan EP. *A Population-Based Study of Idiopathic Transverse Myelitis with Aquaporin-4-IgG and Myelin-Oligodendrocyte-Glycoprotein-IgG Assessment (S11.007)*. 71<sup>st</sup> Meeting of the American Academy of Neurology; Philadelphia 2019. Platform presentation.
14. **Sechi E**, Keegan BM, Kaufmann T, et al. *Unilateral Motor Progression in Multiple Sclerosis: Association with a Single Critical Corticospinal Tract Lesion (P5.2-012)*. 71<sup>st</sup> Meeting of the American Academy of Neurology; Philadelphia 2019. Poster presentation.
15. Asnafi S, Morris PP, Pittock SJ, Weinshenker BG, Palace J, Messina S, **Sechi E**, Flanagan EP. *The Frequency of Longitudinally Extensive Transverse Myelitis in Multiple Sclerosis in the Era of Glial Biomarkers; A Population-Based Study (P4.2-055)*. 71<sup>st</sup> Meeting of the American Academy of Neurology; Philadelphia 2019. Poster presentation.
16. **Sechi E**, Keegan BM, Kaufmann TJ, Kantarci OH, Weinshenker BG, Flanagan EP. *Unilateral motor progression in multiple sclerosis: the impact of single critical corticospinal tract lesions*. ECTRIMS 2018 Berlin. Poster (P460).
17. Mariotto S, Ferrari S, Gastaldi M, Franciotta D, **Sechi E**, [...] Gajofatto A. *Neurofilament light chain serum concentration reflects disease severity in patients with MOG-Ab associated disorders*. ECTRIMS 2018 Berlin. Poster (P1173).
18. **Sechi E**, Morris PP, McKeon A, [...] Flanagan EP. *Glial Fibrillary Acid Protein Immunoglobulin G (GFAP-IgG) Related Myelitis: Characterization and Comparison with Aquaporin-4-IgG Myelitis (S13.006)*. 70<sup>th</sup> AAN Meeting, Los Angeles 2018. Platform presentation.
19. Batzu L, **Sechi E**, Frau C, Mamei G, Ortu R, Sechi G. *Atopic Myelitis: a new European case of a probably underestimated disorder*. 3<sup>rd</sup> Congress of the European Academy of Neurology; Amsterdam 2017. ePresentation: PR3104.
20. Demurtas R, Boadu W, **Sechi E**, Mandia D, Delogu R, Corda D, Sechi G. *Acute, progressive aquaporin-4 antibodies encephalopathy mimicking herpes simplex encephalitis*. 3<sup>rd</sup> Congress of the European Academy of Neurology; Amsterdam 2017. Poster: POD505.
21. Fois C, Rassu AL, **Sechi E**, Addis A, Piredda R, Demurtas R, Mandia D, Sechi G. *Unpredictable seizure-worsening induced by Levetiracetam monotherapy in a patient with focal cortical dysplasia type II*. 2<sup>nd</sup> Congress of the European Academy of Neurology; Copenhagen 2016. Poster: P11131.
22. Rassu AL, Piredda R, Addis A, **Sechi E**, Fois C, Boadu W, Nako E, Sechi G. *Recurrence of Herpes Simplex Encephalitis after 16 years*. 2<sup>nd</sup> Congress of the European Academy of Neurology; Copenhagen 2016. Poster: P32091.
23. Piredda R, **Sechi E**, Rassu AL, Addis A, Urso D, Fois C, Ortu R, Sechi G. *Late Onset Atypical Pantothenate-Kinase Associated Neurodegeneration with Homozygous PANK2 mutation in three Sardinian Siblings*. 2<sup>nd</sup> Congress of the European Academy of Neurology; Copenhagen 2016. Poster: P31124.
24. Addis A, Rassu AL, **Sechi E**, Piredda R, Agrò L, Fois C, Corda DG, Sechi G. *Autoimmune encephalitis in a patient with benign pancreatic neoplasia*. 2<sup>nd</sup> Congress of the European Academy of Neurology; Copenhagen 2016. Poster: P11221.

25. **Sechi E**, Addis A, Piredda R, Rassu AL, Fois C, Batzu L, Sechi G. *Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) with extensive neurologic involvement and neutrophilia*. 2nd Congress of the European Academy of Neurology; Copenhagen 2016. Poster: P32216.
26. Addis A, **Sechi E**, Rassu AL, Piredda R, Sechi GP. *ID 411 – Diffuse hyperpathia in a case of Wernicke’s-like encephalopathy*. 15th European Congress on Clinical Neurophysiology, Brno. Clin Neurophysiol 2016; 127(3):e64–e65.
27. Rassu AL, Fois C, **Sechi E**, Piredda R, Murrighile RM, Porcella V, Sechi GP. *ID 332 – Possible cause of autoimmune encephalopathy in epileptic patient*. 15th European Congress on Clinical Neurophysiology, Brno. Clin Neurophysiol 2016; 127(3):e86.

Poster and Abstract  
Presentations at Professional  
Meetings, Conferences  
(National)

1. **Sechi E**. *Mieliti: Nuove prospettive - Aspetti radiologici delle mieliti* – 52nd Congress of the Italian Neurological Society (Milano, December 3-6 2022). Invited talk.
2. **Sechi E**. *Epidemiologia della MG. CORNER – Il Complemento nelle malattie rare neurologiche* – Expert Meeting, Focus MG. (Roma, November 10th 2022). Invited talk.
3. **Sechi E**. *Valore predittivo e “falsi positivi” nella diagnostica di NMOSD e MOGAD*. 3° Corso di Diagnostica di laboratorio delle malattie Demielinizzanti. (Alghero, October 7-8 2022). Invited talk.
4. **Sechi E**. *Depressione nelle patologie neurologiche autoimmuni*. MALATTIE NEUROLOGICHE E DEPRESSIONE. DALLA CLINICA AL TRATTAMENTO (Sassari 26 November 2021). Invited talk.
5. Doneddu PE, **Sechi E**, Addis A, Sechi G. *Ceftriaxone for Alexander’s disease: a four years follow-up*. XLV Congresso Società Italiana di Neurologia, Cagliari 2014. Poster presentation.
6. **Sechi E**, Doneddu PE, Addis A, Sechi G. *Neuralgic amyotrophy presenting as a Vernet’s syndrome: a case report*. XLV Congresso Società Italiana di Neurologia, Cagliari 2014. Poster presentation.

Books, Book Chapters and Others

1. **Sechi E**, Dean M, Wingerchuk. *Case 2: Rapidly progressive numbness and weakness after soft-tissue abscess*. Mayo Clinic Cases in Neuroimmunology. Edited by McKeon A, Keegan BM, and Tobin WO. Oxford University Press; Jan 18 2022.
2. **Sechi E**, Flanagan EP. *Case 39: Progressive quadriparesis and cancer*. Mayo Clinic Cases in Neuroimmunology. Edited by McKeon A, Keegan BM, and Tobin WO. Oxford University Press; Jan 18 2022.
3. **Sechi E**, Flanagan EP. *Autoimmune Demyelinating Syndromes: Aquaporin-4-IgG-positive NMOSD and MOG - IgG Associated Disorder; Chapter 15*. Piquet AL, Alvarez E (eds.) *Neuroimmunology* (Springer Nature Switzerland AG 2021); [http://doi.org/10.1007/978-3-030-61883-4\\_15](http://doi.org/10.1007/978-3-030-61883-4_15)
4. Sechi G, Fancellu L, Doneddu P and **Sechi E**. *Wernicke–Korsakoff Syndrome*. In: eLS. John Wiley & Sons Ltd, Chichester. 2014; <http://www.els.net> [doi: 10.1002/9780470015902.a0025810]
5. Carai A, Fenu G, **Sechi E** (illustrations). *Approcci chirurgici al basicranio*. Aracne editrice 2010. ISBN: 978-88-548-3228-2.

## Research Grants and Awards

1. **Research Grant “Fondo Giancesini” – 2019/2020 VI Edition**  
Project: “Neurofilamenti sierici a catena leggera e specifici pattern di risonanza magnetica come biomarcatori per la diagnosi precoce di mielopatia acuta e predizione di disabilità”
2. **ECTRIMS Travel Grant – Stockholm 2019**  
Project: “A population-based comparison of cervical spine corticospinal tract lesions in benign and secondary progressive MS”.
3. **Annual Symposium of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology: “Innovative approaches to the diagnosis and treatment of MS and autoimmune neurologic disorders”– 1st Place Poster Session**  
Project: “Neurological Complications and Neural Autoantibody Profiles Associated with Immune Checkpoint Inhibitors”
4. **ECTRIMS Travel Grant – Berlin 2018**  
Project: “Unilateral motor progression in multiple sclerosis: the impact of single critical corticospinal tract lesions”.
5. **Postdoctoral Fellowship Award - Translational Clinical (27/6/2018-26/6/2019)**  
Project: “Defining the clinical and radiologic spectrum of spinal cord involvement of CNS demyelinating disease and assessing its importance in diagnosis and pathophysiology”  
Funded by the Mayo Clinic Center for MS and Autoimmune Neurology.

## Reviewer for international Journals

Clinical Neurology and Neurosurgery; Critical Reviews in Clinical Laboratory Sciences; European Journal of Neurology; Frontiers in Neurology; Multiple Sclerosis and Related Disorders; Multiple Sclerosis Journal; Multiple Sclerosis Journal – Experimental, Translational and Clinical; Neurology; Journal of Alzheimer's Disease; Journal of Neuroimmunology; Journal of Neurology, Neurosurgery and Psychiatry; Journal of the Neurological Sciences.



---

Elia Sechi